New Zealand cannabis firm Greenfern Industries has begun distributing two locally made Good Manufacturing Practice (GMP) medications in Australia via an agreement with Cannvalate.
The company said the distribution deal, through wholly owned Australian subsidiary GFI Pharma, has seen “significant and immediate uptake” of the range by prescribers, with more than A$100,000 in sales so far.
The company plans to make the medicines available in New Zealand once approvals have been obtained.
GFI Pharma is also leveraging Cannvalate’s extensive doctor and pharmacy network to collate real-world data from patients, part of a strategy to research and develop the safety and efficacy of cannabinoid medications.
The relationship extends to Epsilon Healthcare and Canadian manufacturer The Valens Company, both of which are involved in making GFI Pharma’s two medications.
Epsilon recently announced it would make its Queensland-based production facility available to The Valens Company under a long-term partnership.
